The stock prices of Yuhan Corporation and Osstem Implant are strong.

Yuhan Corporation develops the third-generation lung cancer treatment Lecrazah. /Courtesy of Yuhan Corporation

According to the Korea Exchange on the 8th, as of 9:30 a.m., Yuhan Corporation is trading at 136,200 won, up 14,800 won (12.19%) from the previous trading day. The preferred stock of Yuhan Corporation is also trading at 125,000 won, up 16,800 won (15.53%) compared to the previous trading day.

At the same time, Osstem Implant is trading at 25,600 won, up 1,600 won (6.67%).

This is interpreted as a result of the announcement of the clinical phase 3 trial results, which showed expected superior efficacy of RAY combined with amivantamab compared to the competitive drug Tagrisso (osimertinib), licensed to Johnson & Johnson (J&J).

RAY is a lung cancer new drug that Osstem Implant licensed to Yuhan Corporation, and Yuhan Corporation licensed to J&J. Amivantamab is a bispecific antibody anticancer drug developed by J&J.

※ This article has been translated by AI. Share your feedback here.